Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial

Boehringer Ingelheim and Eli Lilly and Company reported that the CARMELINA cardiovascular outcome trial evaluating their diabetes drug Tradjenta met its primary endpoint.